<DOC>
	<DOCNO>NCT01095172</DOCNO>
	<brief_summary>Hypothesis : - That B cell depletion , rather reduce acute rejection , allow minimisation immunosuppression , may lead good graft survival . Aim : - To assess whether addition rituximab low-dose tacrolimus immunosuppression regime allow reduction steroid administration . Objectives : - To assess whether B cell depletion affect graft function , acute rejection complication rate - To assess whether T cell response allotransplantation impair B cell depletion .</brief_summary>
	<brief_title>RituxiMab INDuction Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Adult patient 18 year receive first live donor renal transplant , second first lose acute rejection Patients give write informed consent Women child bear potential take adequate contraception . Previous organ transplant lose acute rejection Patients undergo antibody incompatible transplantation Patients organ transplant Patients previously treat cyclophosphamide , ATG , OKT3 rituximab Patients white cell count 4.0x10^9/L . Patients platelet count 100x10^9/L Patients treat drug strong inhibitor inducer cytochrome P450 , treat terfenadine , astemizole , cisapride lovastatin Patients involve investigational trial non protocol immunosuppressive regimen previous 90 day prior transplant Pregnant breastfeed woman Patients documented history malignancy origins treatment last five year . ( Localised basal cell carcinoma skin permit ) Patients know HIV , Hepatitis B surface antigen Hepatitis C antibody positive Patients opinion Investigator would suitable candidate study participation Women child bear potential willing take adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>Rituximab</keyword>
	<keyword>B cell</keyword>
</DOC>